Home・Lista de Ações・Organon & Co

Organon & Co

Fechado

SetorSaúde

13.73 0.07

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.7

Máximo

13.73

Indicadores-chave
By Trading Economics
Rendimento	-292M -146M
Vendas	98M 1.6B
P/E Médio do Setor	17.539 55.725
EPS	0.8
Rendimento de Dividendos	0.58
Margem de lucro	-9.355
Funcionários	10,000
EBITDA	-38M 371M

Dividendos
By Acuity
Rendimento de Dividendos Médio do Setor	0.58% 2.25%
Próximos Ganhos	9 de nov. de 2026
Próxima data de dividendos	10 de dez. de 2026
Próxima data de ex-dividendo	19 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	42M 3.6B
Abertura anterior	13.66
Fecho anterior	13.73

Sentimento de Notícias

By Acuity

34%

66%

63 / 339 Ranking em Healthcare

Organon & Co Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de set. de 2026, 19:25 UTC

Organon & Co is trading slightly higher, maintaining a routine pattern as it approaches the upper end of its one-month price range.

22 de set. de 2026, 22:01 UTC

Organon & Co is seeing a decline in after-market trading, now near the lower end of its one-month trading range since Tuesday's close.

18 de set. de 2026, 19:16 UTC

Organon & Co is trading roughly flat, showing little change since Thursday's close and remaining near the lower end of its one-month range.

17 de set. de 2026, 23:51 UTC

Organon & Co. is experiencing a modest decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month trading range.

15 de set. de 2026, 19:56 UTC

Event

Organon & Co expects PDUFA action in Q2 2027, shares trading higher since Monday's close. The stock remains near the lower end of its one-month range.

2 de set. de 2026, 20:08 UTC

Organon & Co. shares are trading roughly flat, showing little change since Tuesday's close, amid stability near the upper end of their one-month range.

1 de set. de 2026, 23:01 UTC

Organon & Co. shares are lower in after-market trading, continuing a downward trend amid broader market unease over economic data indicating a growth slowdown.

28 de ago. de 2026, 19:26 UTC

Organon & Co. shares are trading roughly flat, with no specific news identified. The stock remains near the upper end of its one-month trading range.

27 de ago. de 2026, 23:01 UTC

Shares of Organon & Co. traded lower in after-market hours, continuing a decline observed earlier in the session without any specific company news identified.

25 de ago. de 2026, 19:36 UTC

Organon & Co. shares are near unchanged, trading within a narrow range with no specific news identified during Tuesday's session.

24 de ago. de 2026, 23:02 UTC

Organon & Co shares are trading lower in after-market hours. Broader geopolitical tensions, particularly the U.S.-Iran situation, may be influencing market sentiment.

21 de ago. de 2026, 23:41 UTC

Organon & Co. shares are lower in after-hours trading, following a decline from earlier highs and reaching a session low. No specific news was identified.

20 de ago. de 2026, 22:01 UTC

Organon & Co shares are trading lower in after-market hours, continuing a downward trend since Thursday's close without any specific news to explain the movement.

19 de ago. de 2026, 23:01 UTC

Organon & Co shares declined in after-hours trading, reflecting unusual weakness since Wednesday's close. The stock is near the lower end of its one-month range.

18 de ago. de 2026, 23:51 UTC

Organon & Co shares are higher in after-market trading, reaching a maximum cumulative return shortly after Tuesday's close. No specific news was identified.

14 de ago. de 2026, 19:26 UTC

Organon & Co. shares are trading roughly flat, remaining above their 20-day moving average and near the upper end of their one-month range.

13 de ago. de 2026, 23:11 UTC

Organon & Co. shares are trading lower in after-market hours, despite an initial uptick, and remain near the upper end of their one-month trading range.

7 de ago. de 2026, 20:06 UTC

Shares of Organon & Co. are higher today, continuing a trend since Thursday's close amid a broader market increase. No specific company news was identified.

6 de ago. de 2026, 23:11 UTC

Shares of Organon & Co. are trading lower in after-market hours, reflecting routine action within its one-month trading range. No specific news was identified.

Comparação entre Pares

Variação de preço

Organon & Co Previsão

Consenso de Avaliação

By TipRanks

0 ratings

Comprar

Manter

Vender

Com base em 0 analistas que deram avaliações de ações para Organon & Co - Dist nos últimos 3 meses.

Sentimento

By Acuity

63 / 339 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.